No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 5.1x · 10Y median 4.2x · 95th percentile · as of Oct 5, 2026
Annualized revenue (TTM) · by quarter, last 27
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T12:40:14.496Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Quote observation: 2026-10-06T12:40:14.496Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow. Quote observation: 2026-10-06T12:40:14.496Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Quote observation: 2026-10-06T12:40:14.496Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-06T12:40:14.496Z. Latest historical point 2026-10-05.
Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Quote observation: 2026-10-06T12:40:14.496Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter operating cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T12:40:14.496Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter free cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T12:40:14.496Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Enact Holdings Inc. (ACT) stock was $45.87 as of Oct 5, 2026, 4:00 PM EDT, up 1.35% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +27.2% · 3-year avg +21.5%/yr · 5-year avg +22.5%/yr
Enact Holdings, Inc. operates as a private mortgage insurance company in the United States.
Insurance - Specialty · Raleigh, NC
Next Earnings Date
Nov 4, 2026
29 days away
EPS Estimate
1.19
Revenue Est.
$317.97M
Last Quarter Results
EPS
$1.26
vs Estimate
$1.19
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1ACT | $6.40B | $45.87 | +1.35% | +27.20% | +22.54% | N/A | N/A |
| 2PDI | $6.55B | $14.20 | -1.39% | -16.68% | +1.12% | +4.75% | vs ACT |
| 3HWC | $5.94B | $73.18 | +0.12% | +20.37% | +11.40% | +11.24% | vs ACT |
| 4BGC | $5.78B | $12.20 | +3.57% | +33.36% | +18.44% | +11.72% | vs ACT |
| 5MKTX | $5.77B | $164.04 | -0.06% | -1.89% | -16.50% | +1.17% | vs ACT |
| 6VLY | $7.07B | $12.76 | -0.47% | +23.96% | +3.07% | +7.25% | vs ACT |
TTM
5.11
$317.31M
vs Estimate
$315.81M
Consensus Rating
Based on 5 analysts
Average Price Target
$50.20
+9.4% upside
Low
$48.00
Current
$45.87
High
$53.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $1.18 | $1.19 | $1.20 | 3 |
| Quarter ending Dec 2026 | $1.17 | $1.18 | $1.19 | 2 |
| Quarter ending Mar 2027 | $1.26 | $1.27 | $1.28 | 1 |
| Quarter ending Jun 2027 | $1.31 | $1.31 | $1.33 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $4.70 | $4.80 | $4.85 | 4 |
| FY 2027 | $4.87 | $5.06 | $5.27 | 4 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $316.60M | $317.97M | $320.36M | 2 |
| Quarter ending Dec 2026 | $316.85M | $318.22M | $320.61M | 2 |
| Quarter ending Mar 2027 | $318.80M | $320.18M | $322.59M | 1 |
| Quarter ending Jun 2027 | $320.35M | $321.74M | $324.16M | 1 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E uses the consensus EPS estimate for the fiscal year ending Dec 31, 2026, matching Key Metrics.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $1.25B | $1.27B | $1.29B | 3 |
| FY 2027 | $1.27B | $1.29B | $1.30B | 3 |
